The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO TAT 2021 | Pan-FGRF inhibitors in different FGFR alteration types across solid tumours
Cedric Pobel, MD, Gustave Roussy Institute, Villejuif, France, shares results from 4 different Phase I/II clinical trials (NCT01703481, NCT01004224, NCT02052778, and NCT01004224), which assessed how different fibroblast growth factor receptor (FGFR) alteration types affect treatment of various cancers. A total of 92 patients were treated with pan-FGRF inhibitors, and patients with FGFR amplifications demonstrated shorter progression-free survival (PFS) and lower response rates. However, one patient with breast cancer and FGFR amplification had an above-average PFS of 7 months. Overall, patients with cholangiocarcinoma and urothelial cancer had the best responses to treatment. This interview took place during the ESMO TAT 2021 conference.
